Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hawthorn Red Pigment for Refractory Cancer Pain
NCT05561023Phase 1Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Oct 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of Hawthorn red pigment in cancer pain, sponsored by Fujian Medical University Cancer Hospital. Primary endpoints: Adverse Events at 1 month, Serious Adverse Events at 1 month and 3 more. Status: unknown.
02
Drugs
Hawthorn red pigment
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT05561023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05561023.